Difficulty: Medium
Average Score: 72%
Practice
Which of the following mechanisms of action most likely contributes to the treatment of parkinsonism?
Correct answer
B
Rationale
The correct answer is B) The antimuscarinic activity of diphenhydramine contributes to the restoration of striatal dopaminergic-cholinergic neurotransmitter balance in the treatment of parkinsonism. In parkinsonism, there is an imbalance between dopamine and acetylcholine in the brain, leading to motor symptoms. Diphenhydramine, an antimuscarinic agent, helps rebalance this by blocking the muscarinic receptors, which in turn reduces the inhibitory effect of acetylcholine on the dopaminergic pathways.
Option A is incorrect because amantadine acts primarily by enhancing the release of dopamine rather than mimicking its activity. Option C is incorrect as trihexyphenidyl is an anticholinergic medication, not an antihistaminic one. Option D is incorrect as bromocriptine is a dopamine agonist that directly stimulates dopamine receptors, rather than releasing dopamine from intact terminals.
Educationally, understanding the mechanisms of action of drugs used in parkinsonism is crucial for healthcare professionals to make informed decisions in patient care. This knowledge helps in selecting the most appropriate medication based on the underlying pathophysiology of the condition, thereby optimizing treatment outcomes for patients with parkinsonism.
Option A is incorrect because amantadine acts primarily by enhancing the release of dopamine rather than mimicking its activity. Option C is incorrect as trihexyphenidyl is an anticholinergic medication, not an antihistaminic one. Option D is incorrect as bromocriptine is a dopamine agonist that directly stimulates dopamine receptors, rather than releasing dopamine from intact terminals.
Educationally, understanding the mechanisms of action of drugs used in parkinsonism is crucial for healthcare professionals to make informed decisions in patient care. This knowledge helps in selecting the most appropriate medication based on the underlying pathophysiology of the condition, thereby optimizing treatment outcomes for patients with parkinsonism.